DE60201074T2 - Pyrazolopyridinderivate - Google Patents
Pyrazolopyridinderivate Download PDFInfo
- Publication number
- DE60201074T2 DE60201074T2 DE60201074T DE60201074T DE60201074T2 DE 60201074 T2 DE60201074 T2 DE 60201074T2 DE 60201074 T DE60201074 T DE 60201074T DE 60201074 T DE60201074 T DE 60201074T DE 60201074 T2 DE60201074 T2 DE 60201074T2
- Authority
- DE
- Germany
- Prior art keywords
- pyrazolo
- pyridin
- pyrimidinyl
- cyclopentylamino
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 443
- 238000000034 method Methods 0.000 claims abstract description 104
- 230000008569 process Effects 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 120
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 89
- 125000003342 alkenyl group Chemical group 0.000 claims description 69
- -1 dibenzyl-4 - {[3- [2- (cyclopentylamino) pyrimidin-4-yl] -2- (4-methoxyphenyl) pyrazolo [1.5 -a] pyridin-7-yl] amino} butyl Chemical group 0.000 claims description 57
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 55
- 229910052736 halogen Inorganic materials 0.000 claims description 50
- 150000002367 halogens Chemical class 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 238000011321 prophylaxis Methods 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 33
- 230000003612 virological effect Effects 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 32
- 150000001412 amines Chemical class 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 29
- 241001465754 Metazoa Species 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 27
- 206010019973 Herpes virus infection Diseases 0.000 claims description 25
- 239000012453 solvate Substances 0.000 claims description 24
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 23
- 150000004820 halides Chemical class 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 21
- 125000000304 alkynyl group Chemical group 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 15
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 13
- BPAMNDQCSLFBDM-UHFFFAOYSA-N 2-(3-bromophenyl)-n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound BrC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 BPAMNDQCSLFBDM-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 12
- GCHDTEVSZUGMOM-UHFFFAOYSA-N 2-(4-aminophenyl)-n-butyl-3-[2-(butylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(N)=CC=2)=N1 GCHDTEVSZUGMOM-UHFFFAOYSA-N 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 11
- IUEPWZMCLQDBOR-UHFFFAOYSA-N 4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 IUEPWZMCLQDBOR-UHFFFAOYSA-N 0.000 claims description 9
- 125000005336 allyloxy group Chemical group 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- URZFGPOTFWRSEP-UHFFFAOYSA-N n'-[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]butane-1,4-diamine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCCCN)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 URZFGPOTFWRSEP-UHFFFAOYSA-N 0.000 claims description 9
- CLOLNRNDHYJZSS-UHFFFAOYSA-N 2-(3-aminophenyl)-n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound NC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 CLOLNRNDHYJZSS-UHFFFAOYSA-N 0.000 claims description 8
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 8
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 8
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 8
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 8
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 8
- 230000001590 oxidative effect Effects 0.000 claims description 8
- DUDDTXXZIYPHCW-UHFFFAOYSA-N 4-[7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-n-cyclopentylpyrimidin-2-amine Chemical compound COC1=CC=CC(C=2C(=C3C=CC=C(Cl)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 DUDDTXXZIYPHCW-UHFFFAOYSA-N 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 229960004150 aciclovir Drugs 0.000 claims description 7
- 239000003443 antiviral agent Substances 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- FMFPUOWQBSQZCG-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 FMFPUOWQBSQZCG-UHFFFAOYSA-N 0.000 claims description 7
- 229940093257 valacyclovir Drugs 0.000 claims description 7
- AZQWIDZJMCVVCL-UHFFFAOYSA-N 2-(3-bromo-4-chlorophenyl)-n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=C(Br)C(Cl)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 AZQWIDZJMCVVCL-UHFFFAOYSA-N 0.000 claims description 6
- NSNVVQOTZRQGMG-UHFFFAOYSA-N 3-[2-(cyclopentylamino)pyrimidin-4-yl]-n-cyclopropyl-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NC2CC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 NSNVVQOTZRQGMG-UHFFFAOYSA-N 0.000 claims description 6
- LWTKNKOXQOKNHQ-UHFFFAOYSA-N 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]benzonitrile Chemical compound N#CC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 LWTKNKOXQOKNHQ-UHFFFAOYSA-N 0.000 claims description 6
- DUBQKOZKJQTPCG-UHFFFAOYSA-N 4-[2-(3-bromophenyl)-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-3-yl]-n-cyclopentylpyrimidin-2-amine Chemical compound BrC1=CC=CC(C=2C(=C3C=CC=C(N3N=2)N2CCCC2)C=2N=C(NC3CCCC3)N=CC=2)=C1 DUBQKOZKJQTPCG-UHFFFAOYSA-N 0.000 claims description 6
- OXZGCWROXDNAAC-UHFFFAOYSA-N 4-[3-[2-(cyclopentylamino)pyrimidin-4-yl]-7-(cyclopropylamino)pyrazolo[1,5-a]pyridin-2-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=NN(C(NC2CC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 OXZGCWROXDNAAC-UHFFFAOYSA-N 0.000 claims description 6
- GZPOEZSVXJIRAA-UHFFFAOYSA-N 4-[7-(cyclopropylamino)-3-[2-(cyclopropylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=NN(C(NC2CC2)=CC=C2)C2=C1C1=CC=NC(NC2CC2)=N1 GZPOEZSVXJIRAA-UHFFFAOYSA-N 0.000 claims description 6
- OMODOIMGTYNSSP-UHFFFAOYSA-N 4-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-n-cyclopentyl-5,6-dimethylpyrimidin-2-amine Chemical compound CC1=CC=CC(C=2C(=C3C=CC=C(Cl)N3N=2)C=2C(=C(C)N=C(NC3CCCC3)N=2)C)=C1 OMODOIMGTYNSSP-UHFFFAOYSA-N 0.000 claims description 6
- XFZVTNMJVGNMEI-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound CC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 XFZVTNMJVGNMEI-UHFFFAOYSA-N 0.000 claims description 6
- GJKBRPIYUIZXFG-UHFFFAOYSA-N n-cyclopentyl-4-[2-(4-methoxyphenyl)-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(=CC=C2)N3CCCC3)C2=C1C1=CC=NC(NC2CCCC2)=N1 GJKBRPIYUIZXFG-UHFFFAOYSA-N 0.000 claims description 6
- RADJASMYJQAUJI-UHFFFAOYSA-N 2-(2-bromophenyl)-n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound BrC1=CC=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 RADJASMYJQAUJI-UHFFFAOYSA-N 0.000 claims description 5
- BZZXNPCNQJMBCD-UHFFFAOYSA-N 2-(3-bromo-4-methoxyphenyl)-n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=C(Br)C(OC)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 BZZXNPCNQJMBCD-UHFFFAOYSA-N 0.000 claims description 5
- RJKZCZWMDVDIEG-UHFFFAOYSA-N 2-[4-(benzylamino)phenyl]-n-butyl-3-[2-(butylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(NCC=3C=CC=CC=3)=CC=2)=N1 RJKZCZWMDVDIEG-UHFFFAOYSA-N 0.000 claims description 5
- HZEXXIRPHHCCLZ-UHFFFAOYSA-N 3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)-n-(2-morpholin-4-ylethyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCN2CCOCC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 HZEXXIRPHHCCLZ-UHFFFAOYSA-N 0.000 claims description 5
- RVOLAJPEIJSJIP-UHFFFAOYSA-N 3-[2-(cyclopropylamino)pyrimidin-4-yl]-n-(2-methoxyethyl)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound N=1N2C(NCCOC)=CC=CC2=C(C=2N=C(NC3CC3)N=CC=2)C=1C1=CC=C(OC)C=C1 RVOLAJPEIJSJIP-UHFFFAOYSA-N 0.000 claims description 5
- OCBBEFAPAGBLDV-UHFFFAOYSA-N 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenol Chemical compound OC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 OCBBEFAPAGBLDV-UHFFFAOYSA-N 0.000 claims description 5
- YZYKMRMDEPRYFE-UHFFFAOYSA-N 4-[2-(4-methoxyphenyl)-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(=CC=C2)N3CCCC3)C2=C1C1=CC=NC(N)=N1 YZYKMRMDEPRYFE-UHFFFAOYSA-N 0.000 claims description 5
- FBSUZOMOEAPWGI-UHFFFAOYSA-N 4-[7-(cyclopentylamino)-3-[2-(cyclopropylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C1=CC=NC(NC2CC2)=N1 FBSUZOMOEAPWGI-UHFFFAOYSA-N 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- IPZNCOAQNRRMNG-UHFFFAOYSA-N n-butyl-3-[2-(butylamino)pyrimidin-4-yl]-2-[4-(cyclopropylmethylamino)phenyl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(NCC3CC3)=CC=2)=N1 IPZNCOAQNRRMNG-UHFFFAOYSA-N 0.000 claims description 5
- BZFWCQOKAPYFNZ-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound COC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 BZFWCQOKAPYFNZ-UHFFFAOYSA-N 0.000 claims description 5
- BVLPZDZJOMPDER-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-[3-(cyclopropylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1CC1COC(C=1)=CC=CC=1C(C(=C1C=CC=2)C=3N=C(NC4CCCC4)N=CC=3)=NN1C=2NC1CCCC1 BVLPZDZJOMPDER-UHFFFAOYSA-N 0.000 claims description 5
- DCORZUCVQOXEOG-UHFFFAOYSA-N n-cyclopentyl-4-[2-(4-methoxyphenyl)-7-morpholin-4-ylpyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(=CC=C2)N3CCOCC3)C2=C1C1=CC=NC(NC2CCCC2)=N1 DCORZUCVQOXEOG-UHFFFAOYSA-N 0.000 claims description 5
- FYDOYXKIRVHWEC-UHFFFAOYSA-N n-cyclopropyl-3-[2-(cyclopropylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NC2CC2)=CC=C2)C2=C1C1=CC=NC(NC2CC2)=N1 FYDOYXKIRVHWEC-UHFFFAOYSA-N 0.000 claims description 5
- NOAMJCVNUJMSBD-UHFFFAOYSA-N n-cyclopropyl-4-[2-(4-methoxyphenyl)-7-morpholin-4-ylpyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(=CC=C2)N3CCOCC3)C2=C1C1=CC=NC(NC2CC2)=N1 NOAMJCVNUJMSBD-UHFFFAOYSA-N 0.000 claims description 5
- QWLYSDRFTNRBBK-UHFFFAOYSA-N 1-[4-[[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCCCNC(=O)NS(=O)(=O)C=2C=CC(C)=CC=2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 QWLYSDRFTNRBBK-UHFFFAOYSA-N 0.000 claims description 4
- IKLFKJPFQIXZCB-UHFFFAOYSA-N 2-(3-amino-4-chlorophenyl)-n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=C(Cl)C(N)=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 IKLFKJPFQIXZCB-UHFFFAOYSA-N 0.000 claims description 4
- LZKPXAYLIVWHIR-UHFFFAOYSA-N 2-(3-azidophenyl)-n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound [N-]=[N+]=NC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 LZKPXAYLIVWHIR-UHFFFAOYSA-N 0.000 claims description 4
- HFEYWTFIOJKIJG-UHFFFAOYSA-N 2-(3-bromophenyl)-3-[2-(cyclopentylamino)pyrimidin-4-yl]-n-cyclopropylpyrazolo[1,5-a]pyridin-7-amine Chemical compound BrC1=CC=CC(C=2C(=C3C=CC=C(NC4CC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 HFEYWTFIOJKIJG-UHFFFAOYSA-N 0.000 claims description 4
- BRORWJUKGAHUPQ-UHFFFAOYSA-N 2-(3-bromophenyl)-n-cyclopentyl-3-[2-(cyclopropylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound BrC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CC3)N=CC=2)=C1 BRORWJUKGAHUPQ-UHFFFAOYSA-N 0.000 claims description 4
- LYAAIUHFSVIZHL-UHFFFAOYSA-N 2-(3-bromophenyl)-n-cyclopropyl-3-[2-(cyclopropylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound BrC1=CC=CC(C=2C(=C3C=CC=C(NC4CC4)N3N=2)C=2N=C(NC3CC3)N=CC=2)=C1 LYAAIUHFSVIZHL-UHFFFAOYSA-N 0.000 claims description 4
- LZHBQDAZVHGFHJ-UHFFFAOYSA-N 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)pyrimidin-4-yl]-n-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound N=1N2C(NCCOC)=CC=CC2=C(C=2N=C(NC3CCCC3)N=CC=2)C=1C1=CC=CC(Cl)=C1 LZHBQDAZVHGFHJ-UHFFFAOYSA-N 0.000 claims description 4
- YIBNLVFHWFNOQI-UHFFFAOYSA-N 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)pyrimidin-4-yl]-n-cyclopropylpyrazolo[1,5-a]pyridin-7-amine Chemical compound ClC1=CC=CC(C=2C(=C3C=CC=C(NC4CC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 YIBNLVFHWFNOQI-UHFFFAOYSA-N 0.000 claims description 4
- NLNUPJVGCWUSNO-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound ClC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 NLNUPJVGCWUSNO-UHFFFAOYSA-N 0.000 claims description 4
- ZWJRQGJBCWTXAI-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-cyclopropyl-3-[2-(cyclopropylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound ClC1=CC=CC(C=2C(=C3C=CC=C(NC4CC4)N3N=2)C=2N=C(NC3CC3)N=CC=2)=C1 ZWJRQGJBCWTXAI-UHFFFAOYSA-N 0.000 claims description 4
- QDYLEYFQUPNZPC-UHFFFAOYSA-N 2-(4-anilinophenyl)-n-butyl-3-[2-(butylamino)pyrimidin-4-yl]-n-phenylpyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(N3N=C2C=2C=CC(NC=3C=CC=CC=3)=CC=2)N(CCCC)C=2C=CC=CC=2)=N1 QDYLEYFQUPNZPC-UHFFFAOYSA-N 0.000 claims description 4
- FSYBMNDKWAAPFI-UHFFFAOYSA-N 2-[4-(cyclobutylmethoxy)phenyl]-n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1CCC1COC(C=C1)=CC=C1C(C(=C1C=CC=2)C=3N=C(NC4CCCC4)N=CC=3)=NN1C=2NC1CCCC1 FSYBMNDKWAAPFI-UHFFFAOYSA-N 0.000 claims description 4
- DOPXOLYXUQQAGU-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(3-bromophenyl)-n-cyclopentylpyrazolo[1,5-a]pyridin-7-amine Chemical compound NC1=NC=CC(C2=C3C=CC=C(NC4CCCC4)N3N=C2C=2C=C(Br)C=CC=2)=N1 DOPXOLYXUQQAGU-UHFFFAOYSA-N 0.000 claims description 4
- YYFSVZHWEACRRX-UHFFFAOYSA-N 3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(3-fluorophenyl)-n-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound N=1N2C(NCCOC)=CC=CC2=C(C=2N=C(NC3CCCC3)N=CC=2)C=1C1=CC=CC(F)=C1 YYFSVZHWEACRRX-UHFFFAOYSA-N 0.000 claims description 4
- QYGNAMDJSFPVGI-UHFFFAOYSA-N 3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(3-methoxyphenyl)-n,n-dimethylpyrazolo[1,5-a]pyridin-7-amine Chemical compound COC1=CC=CC(C=2C(=C3C=CC=C(N3N=2)N(C)C)C=2N=C(NC3CCCC3)N=CC=2)=C1 QYGNAMDJSFPVGI-UHFFFAOYSA-N 0.000 claims description 4
- HISQMDKDLBLMKM-UHFFFAOYSA-N 3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(N)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 HISQMDKDLBLMKM-UHFFFAOYSA-N 0.000 claims description 4
- QXQYIVLLEKFFSF-UHFFFAOYSA-N 3-[2-(cyclopentylamino)pyrimidin-4-yl]-n-(2-methoxyethyl)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound N=1N2C(NCCOC)=CC=CC2=C(C=2N=C(NC3CCCC3)N=CC=2)C=1C1=CC=C(OC)C=C1 QXQYIVLLEKFFSF-UHFFFAOYSA-N 0.000 claims description 4
- KSSZHVRVJVWUGH-UHFFFAOYSA-N 3-[2-(cyclopentylamino)pyrimidin-4-yl]-n-cyclopropyl-2-[4-(cyclopropylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1CC1COC(C=C1)=CC=C1C(C(=C1C=CC=2)C=3N=C(NC4CCCC4)N=CC=3)=NN1C=2NC1CC1 KSSZHVRVJVWUGH-UHFFFAOYSA-N 0.000 claims description 4
- TWMBFFPRWBHQMZ-UHFFFAOYSA-N 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 TWMBFFPRWBHQMZ-UHFFFAOYSA-N 0.000 claims description 4
- WBDOSLTTZIURRR-UHFFFAOYSA-N 4-[2-(3-aminophenyl)-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-3-yl]-n-cyclopentylpyrimidin-2-amine Chemical compound NC1=CC=CC(C=2C(=C3C=CC=C(N3N=2)N2CCCC2)C=2N=C(NC3CCCC3)N=CC=2)=C1 WBDOSLTTZIURRR-UHFFFAOYSA-N 0.000 claims description 4
- YMRBSQVPVTYLPC-UHFFFAOYSA-N 4-[3-(2-aminopyrimidin-4-yl)-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-2-yl]phenol Chemical compound NC1=NC=CC(C2=C3C=CC=C(N3N=C2C=2C=CC(O)=CC=2)N2CCCC2)=N1 YMRBSQVPVTYLPC-UHFFFAOYSA-N 0.000 claims description 4
- ROZOPWJQDHFSMY-UHFFFAOYSA-N 4-[3-[2-(cyclopentylamino)pyrimidin-4-yl]-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-2-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=NN(C(=CC=C2)N3CCCC3)C2=C1C1=CC=NC(NC2CCCC2)=N1 ROZOPWJQDHFSMY-UHFFFAOYSA-N 0.000 claims description 4
- GSTTYBVHTHYNPK-QUSZHGRCSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[4-[7-(butylamino)-3-[2-(butylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]pentanamide Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(NC(=O)CCCC[C@H]3[C@H]4NC(=O)N[C@H]4CS3)=CC=2)=N1 GSTTYBVHTHYNPK-QUSZHGRCSA-N 0.000 claims description 4
- 125000006309 butyl amino group Chemical group 0.000 claims description 4
- KYYNKXUDJBNRHP-UHFFFAOYSA-N n-[3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 KYYNKXUDJBNRHP-UHFFFAOYSA-N 0.000 claims description 4
- OFDNOMWOVFJWOC-UHFFFAOYSA-N n-[3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 OFDNOMWOVFJWOC-UHFFFAOYSA-N 0.000 claims description 4
- HWQLSJWSPAPOPG-UHFFFAOYSA-N n-[4-[[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]methanesulfonamide Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCCCNS(C)(=O)=O)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 HWQLSJWSPAPOPG-UHFFFAOYSA-N 0.000 claims description 4
- SZCIIHPOWRLCIH-UHFFFAOYSA-N n-butyl-3-[2-(butylamino)pyrimidin-4-yl]-2-(4-morpholin-4-ylphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(=CC=2)N2CCOCC2)=N1 SZCIIHPOWRLCIH-UHFFFAOYSA-N 0.000 claims description 4
- UGJRRSOZEFGMRQ-UHFFFAOYSA-N n-butyl-3-[2-(butylamino)pyrimidin-4-yl]-2-(4-phenylphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 UGJRRSOZEFGMRQ-UHFFFAOYSA-N 0.000 claims description 4
- AJKBXNMWNLJVSK-UHFFFAOYSA-N n-butyl-3-[2-(butylamino)pyrimidin-4-yl]-2-(4-prop-1-en-2-ylphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(=CC=2)C(C)=C)=N1 AJKBXNMWNLJVSK-UHFFFAOYSA-N 0.000 claims description 4
- NXFKTFKZZARTRL-UHFFFAOYSA-N n-butyl-3-[2-(butylamino)pyrimidin-4-yl]-2-[4-(cyclohexylamino)phenyl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(NC3CCCCC3)=CC=2)=N1 NXFKTFKZZARTRL-UHFFFAOYSA-N 0.000 claims description 4
- FLWPUQVWWOQJCR-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)-5,6-dimethylpyrimidin-4-yl]-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound CC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2C(=C(C)N=C(NC3CCCC3)N=2)C)=C1 FLWPUQVWWOQJCR-UHFFFAOYSA-N 0.000 claims description 4
- XASCGNKLCRYJKI-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(3-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound FC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 XASCGNKLCRYJKI-UHFFFAOYSA-N 0.000 claims description 4
- QOUDPRBVRCZZAF-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(3-phenylphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1CCCC1NC1=NC=CC(C2=C3C=CC=C(NC4CCCC4)N3N=C2C=2C=C(C=CC=2)C=2C=CC=CC=2)=N1 QOUDPRBVRCZZAF-UHFFFAOYSA-N 0.000 claims description 4
- NYRPDSRXHRVHKP-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-phenoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1CCCC1NC1=NC=CC(C2=C3C=CC=C(NC4CCCC4)N3N=C2C=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 NYRPDSRXHRVHKP-UHFFFAOYSA-N 0.000 claims description 4
- LLXJQKCGPYINCG-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-prop-2-enoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=CC(OCC=C)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 LLXJQKCGPYINCG-UHFFFAOYSA-N 0.000 claims description 4
- RBJUJGPCYJPFCI-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound FC(F)(F)C1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 RBJUJGPCYJPFCI-UHFFFAOYSA-N 0.000 claims description 4
- YSBVWPYUIWKAPA-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-[4-(cyclopropylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1CC1COC(C=C1)=CC=C1C(C(=C1C=CC=2)C=3N=C(NC4CCCC4)N=CC=3)=NN1C=2NC1CCCC1 YSBVWPYUIWKAPA-UHFFFAOYSA-N 0.000 claims description 4
- DNJDAOUZXFKWRM-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-phenylpyrazolo[1,5-a]pyridin-7-amine Chemical compound C1CCCC1NC1=NC=CC(C2=C3C=CC=C(NC4CCCC4)N3N=C2C=2C=CC=CC=2)=N1 DNJDAOUZXFKWRM-UHFFFAOYSA-N 0.000 claims description 4
- KSKOOGUWUXDAIN-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopropylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C1=CC=NC(NC2CC2)=N1 KSKOOGUWUXDAIN-UHFFFAOYSA-N 0.000 claims description 4
- YFDVTDKCHFIORO-UHFFFAOYSA-N n-cyclopentyl-4-[2-(3-phenylphenyl)-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound C1CCCC1NC1=NC=CC(C2=C3C=CC=C(N3N=C2C=2C=C(C=CC=2)C=2C=CC=CC=2)N2CCCC2)=N1 YFDVTDKCHFIORO-UHFFFAOYSA-N 0.000 claims description 4
- XOCAXFBXUXTLAV-UHFFFAOYSA-N n-cyclopropyl-3-[2-(cyclopropylamino)pyrimidin-4-yl]-2-[4-(cyclopropylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1CC1COC(C=C1)=CC=C1C(C(=C1C=CC=2)C=3N=C(NC4CC4)N=CC=3)=NN1C=2NC1CC1 XOCAXFBXUXTLAV-UHFFFAOYSA-N 0.000 claims description 4
- UZYOKGJMTACFLK-UHFFFAOYSA-N tert-butyl n-[n'-[4-[[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]carbamate Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCCCNC(NC(=O)OC(C)(C)C)=NC(=O)OC(C)(C)C)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 UZYOKGJMTACFLK-UHFFFAOYSA-N 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- MCYNAHONGQXOIV-UHFFFAOYSA-N 2-(4-anilinophenyl)-n-butyl-3-[2-(butylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(NC=3C=CC=CC=3)=CC=2)=N1 MCYNAHONGQXOIV-UHFFFAOYSA-N 0.000 claims description 3
- BRXUKKJUJGQKCF-UHFFFAOYSA-N 2-(4-butoxyphenyl)-n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=CC(OCCCC)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 BRXUKKJUJGQKCF-UHFFFAOYSA-N 0.000 claims description 3
- UENOPHWRHNSCII-UHFFFAOYSA-N 2-[4-[[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]guanidine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCCCNC(N)=N)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 UENOPHWRHNSCII-UHFFFAOYSA-N 0.000 claims description 3
- YYFPOOZYHPFEKB-UHFFFAOYSA-N 2-[[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]-1-pyrrolidin-1-ylethanone Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCC(=O)N2CCCC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 YYFPOOZYHPFEKB-UHFFFAOYSA-N 0.000 claims description 3
- WGCAOYVEHYBUCT-UHFFFAOYSA-N 3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(3-methoxyphenyl)-n-propan-2-ylpyrazolo[1,5-a]pyridin-7-amine Chemical compound COC1=CC=CC(C=2C(=C3C=CC=C(NC(C)C)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 WGCAOYVEHYBUCT-UHFFFAOYSA-N 0.000 claims description 3
- BQTVXODZORGWDG-UHFFFAOYSA-N 3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(3-methylphenyl)-n-propan-2-ylpyrazolo[1,5-a]pyridin-7-amine Chemical compound N=1N2C(NC(C)C)=CC=CC2=C(C=2N=C(NC3CCCC3)N=CC=2)C=1C1=CC=CC(C)=C1 BQTVXODZORGWDG-UHFFFAOYSA-N 0.000 claims description 3
- UYJVTDSQXZGSHB-UHFFFAOYSA-N 3-[2-(cyclopropylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)-n-(2-morpholin-4-ylethyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCN2CCOCC2)=CC=C2)C2=C1C1=CC=NC(NC2CC2)=N1 UYJVTDSQXZGSHB-UHFFFAOYSA-N 0.000 claims description 3
- WGEYMTPFWCAKOC-UHFFFAOYSA-N 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 WGEYMTPFWCAKOC-UHFFFAOYSA-N 0.000 claims description 3
- XWZGAKRBMROWPJ-UHFFFAOYSA-N 4-[2-(3-bromophenyl)-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound NC1=NC=CC(C2=C3C=CC=C(N3N=C2C=2C=C(Br)C=CC=2)N2CCCC2)=N1 XWZGAKRBMROWPJ-UHFFFAOYSA-N 0.000 claims description 3
- CDOYIVPLMXHLON-UHFFFAOYSA-N 4-[2-(3-chlorophenyl)-7-morpholin-4-ylpyrazolo[1,5-a]pyridin-3-yl]-n-cyclopentylpyrimidin-2-amine Chemical compound ClC1=CC=CC(C=2C(=C3C=CC=C(N3N=2)N2CCOCC2)C=2N=C(NC3CCCC3)N=CC=2)=C1 CDOYIVPLMXHLON-UHFFFAOYSA-N 0.000 claims description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- ACCLKFBRTAJBEI-UHFFFAOYSA-N ethyl 2-[4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OCC)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 ACCLKFBRTAJBEI-UHFFFAOYSA-N 0.000 claims description 3
- YQXCSFIFBXSBTR-UHFFFAOYSA-N n'-[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]ethane-1,2-diamine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCN)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 YQXCSFIFBXSBTR-UHFFFAOYSA-N 0.000 claims description 3
- VLUHLWUXPWMXHA-UHFFFAOYSA-N n-butyl-3-[2-(butylamino)pyrimidin-4-yl]-2-[4-(dimethylamino)phenyl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(=CC=2)N(C)C)=N1 VLUHLWUXPWMXHA-UHFFFAOYSA-N 0.000 claims description 3
- RXWCCSNINIJPDY-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(3-thiophen-2-ylphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1CCCC1NC1=NC=CC(C2=C3C=CC=C(NC4CCCC4)N3N=C2C=2C=C(C=CC=2)C=2SC=CC=2)=N1 RXWCCSNINIJPDY-UHFFFAOYSA-N 0.000 claims description 3
- MSYMQUSFKJPTBW-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-[4-(2-methylpropoxy)phenyl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1=CC(OCC(C)C)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 MSYMQUSFKJPTBW-UHFFFAOYSA-N 0.000 claims description 3
- ZRTFWADTSDLSRT-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopropylamino)pyrimidin-4-yl]-2-(3-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound FC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CC3)N=CC=2)=C1 ZRTFWADTSDLSRT-UHFFFAOYSA-N 0.000 claims description 3
- ZBPANWLHZWXUOF-UHFFFAOYSA-N n-cyclopentyl-4-[2-(3-fluorophenyl)-7-morpholin-4-ylpyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound FC1=CC=CC(C=2C(=C3C=CC=C(N3N=2)N2CCOCC2)C=2N=C(NC3CCCC3)N=CC=2)=C1 ZBPANWLHZWXUOF-UHFFFAOYSA-N 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- CTLCJJPQDYDSQF-UHFFFAOYSA-N pyrazolo[1,5-a]pyridin-7-amine Chemical compound NC1=CC=CC2=CC=NN12 CTLCJJPQDYDSQF-UHFFFAOYSA-N 0.000 claims description 3
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims description 2
- VMVZADUSLUWEOO-UHFFFAOYSA-N n-[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]-n'-diethoxyphosphorylbutane-1,4-diamine Chemical compound N=1N2C(NCCCCNP(=O)(OCC)OCC)=CC=CC2=C(C=2N=C(NC3CCCC3)N=CC=2)C=1C1=CC=C(OC)C=C1 VMVZADUSLUWEOO-UHFFFAOYSA-N 0.000 claims description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N Butanol Natural products CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 306
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 194
- 238000005160 1H NMR spectroscopy Methods 0.000 description 169
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 144
- 239000007787 solid Substances 0.000 description 120
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 108
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
- 239000000243 solution Substances 0.000 description 97
- 239000000203 mixture Substances 0.000 description 92
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 74
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 72
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 70
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 66
- 238000006243 chemical reaction Methods 0.000 description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- 238000003818 flash chromatography Methods 0.000 description 47
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- 239000002585 base Substances 0.000 description 41
- 238000001914 filtration Methods 0.000 description 39
- 239000006260 foam Substances 0.000 description 37
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 36
- 235000019341 magnesium sulphate Nutrition 0.000 description 36
- 239000012267 brine Substances 0.000 description 35
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 35
- 239000002904 solvent Substances 0.000 description 35
- 239000011541 reaction mixture Substances 0.000 description 33
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 32
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 28
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 25
- 125000000623 heterocyclic group Chemical group 0.000 description 23
- 235000019441 ethanol Nutrition 0.000 description 22
- 238000009472 formulation Methods 0.000 description 22
- 239000010410 layer Substances 0.000 description 22
- 239000012044 organic layer Substances 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- 239000012442 inert solvent Substances 0.000 description 17
- 229920006395 saturated elastomer Polymers 0.000 description 17
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 16
- 235000017557 sodium bicarbonate Nutrition 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 208000036142 Viral infection Diseases 0.000 description 15
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 15
- 230000009385 viral infection Effects 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 235000020357 syrup Nutrition 0.000 description 13
- 239000006188 syrup Substances 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 12
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 12
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- GXZDYRYYNXYPMQ-UHFFFAOYSA-N 2-chloro-6-methylpyridine Chemical compound CC1=CC=CC(Cl)=N1 GXZDYRYYNXYPMQ-UHFFFAOYSA-N 0.000 description 10
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 239000011701 zinc Substances 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 9
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 150000002576 ketones Chemical class 0.000 description 9
- 239000011777 magnesium Substances 0.000 description 9
- BZRMUMBJGGACCU-UHFFFAOYSA-N 2-(4-bromophenyl)-n-butyl-3-[2-(butylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(Br)=CC=2)=N1 BZRMUMBJGGACCU-UHFFFAOYSA-N 0.000 description 8
- 0 CC(c1c(cccc2*)[n]2nc1C1=CCC(C)=CC=C1)=O Chemical compound CC(c1c(cccc2*)[n]2nc1C1=CCC(C)=CC=C1)=O 0.000 description 8
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 8
- 241000701027 Human herpesvirus 6 Species 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 8
- 208000037803 restenosis Diseases 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- QVXFHUXIURSBSR-UHFFFAOYSA-N 4-[7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-n-cyclopentylpyrimidin-2-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(Cl)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 QVXFHUXIURSBSR-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 150000002736 metal compounds Chemical class 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000007800 oxidant agent Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 6
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 6
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 6
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- KZTNICPUZFGBMA-UHFFFAOYSA-N 1-[7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound C1=CC(OC)=CC=C1C1=NN(C(Cl)=CC=C2)C2=C1C(C)=O KZTNICPUZFGBMA-UHFFFAOYSA-N 0.000 description 5
- IOOJBDSYMIVHQI-UHFFFAOYSA-N 2-cyclopentylguanidine;hydrochloride Chemical compound Cl.NC(N)=NC1CCCC1 IOOJBDSYMIVHQI-UHFFFAOYSA-N 0.000 description 5
- QPQXBPKGZMTERY-UHFFFAOYSA-N 4-[7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-n-cyclopropylpyrimidin-2-amine Chemical compound C1=CC(OC)=CC=C1C1=NN(C(Cl)=CC=C2)C2=C1C1=CC=NC(NC2CC2)=N1 QPQXBPKGZMTERY-UHFFFAOYSA-N 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 208000007514 Herpes zoster Diseases 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241001529453 unidentified herpesvirus Species 0.000 description 5
- JKSFFWDMVWTOJR-BUHFOSPRSA-N (e)-1-[2-(3-bromophenyl)-7-(cyclopentylamino)pyrazolo[1,5-a]pyridin-3-yl]-3-(dimethylamino)prop-2-en-1-one Chemical compound C=1C=CC2=C(C(=O)/C=C/N(C)C)C(C=3C=C(Br)C=CC=3)=NN2C=1NC1CCCC1 JKSFFWDMVWTOJR-BUHFOSPRSA-N 0.000 description 4
- NZMHTGBCRKCFJK-SDNWHVSQSA-N (e)-1-[2-(3-bromophenyl)-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-3-yl]-3-(dimethylamino)prop-2-en-1-one Chemical compound C=1C=CC2=C(C(=O)/C=C/N(C)C)C(C=3C=C(Br)C=CC=3)=NN2C=1N1CCCC1 NZMHTGBCRKCFJK-SDNWHVSQSA-N 0.000 description 4
- DTZGDIWYVFWFGQ-FOCLMDBBSA-N (e)-1-[7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-3-(dimethylamino)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C(=O)\C=C\N(C)C DTZGDIWYVFWFGQ-FOCLMDBBSA-N 0.000 description 4
- NDDMBRMVULNPTJ-DTQAZKPQSA-N (e)-3-(dimethylamino)-1-[2-(4-methoxyphenyl)-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-3-yl]prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C1=NN(C(=CC=C2)N3CCCC3)C2=C1C(=O)\C=C\N(C)C NDDMBRMVULNPTJ-DTQAZKPQSA-N 0.000 description 4
- KJZWORXGGBLILT-UHFFFAOYSA-N 1-(3-bromophenyl)-2-(6-chloropyridin-2-yl)ethanone Chemical compound ClC1=CC=CC(CC(=O)C=2C=C(Br)C=CC=2)=N1 KJZWORXGGBLILT-UHFFFAOYSA-N 0.000 description 4
- PMBJGLYUBXVTAK-UHFFFAOYSA-N 1-[2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound N=1N2C(Cl)=CC=CC2=C(C(=O)C)C=1C1=CC=CC(Br)=C1 PMBJGLYUBXVTAK-UHFFFAOYSA-N 0.000 description 4
- SZYRBMZGMDOLAB-UHFFFAOYSA-N 1-[2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]prop-2-yn-1-one Chemical compound N=1N2C(Cl)=CC=CC2=C(C(=O)C#C)C=1C1=CC=CC(Br)=C1 SZYRBMZGMDOLAB-UHFFFAOYSA-N 0.000 description 4
- RCNAJAYZHRDZBS-UHFFFAOYSA-N 1-[7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]prop-2-yn-1-one Chemical compound C1=CC(OC)=CC=C1C1=NN(C(Cl)=CC=C2)C2=C1C(=O)C#C RCNAJAYZHRDZBS-UHFFFAOYSA-N 0.000 description 4
- KVENROGIMCMFJJ-UHFFFAOYSA-N 2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridine Chemical compound N=1N2C(Cl)=CC=CC2=CC=1C1=CC=CC(Br)=C1 KVENROGIMCMFJJ-UHFFFAOYSA-N 0.000 description 4
- JGJRBTBIBBCGEL-UHFFFAOYSA-N 7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridine-3-carbaldehyde Chemical compound CC1=CC=CC(C=2C(=C3C=CC=C(Cl)N3N=2)C=O)=C1 JGJRBTBIBBCGEL-UHFFFAOYSA-N 0.000 description 4
- FYHDEKUEAVBKRT-UHFFFAOYSA-N 7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine Chemical compound C1=CC(OC)=CC=C1C1=NN2C(Cl)=CC=CC2=C1 FYHDEKUEAVBKRT-UHFFFAOYSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical group Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000001409 amidines Chemical class 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 4
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 4
- 150000002085 enols Chemical class 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000012038 nucleophile Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 4
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- JBRLWUNBLVMLAD-OUKQBFOZSA-N (e)-1-[2-(3-bromo-4-chlorophenyl)-7-(cyclopentylamino)pyrazolo[1,5-a]pyridin-3-yl]-3-(dimethylamino)prop-2-en-1-one Chemical compound C=1C=CC2=C(C(=O)/C=C/N(C)C)C(C=3C=C(Br)C(Cl)=CC=3)=NN2C=1NC1CCCC1 JBRLWUNBLVMLAD-OUKQBFOZSA-N 0.000 description 3
- UQCOEWMOQOBMLV-BUHFOSPRSA-N (e)-1-[2-(3-bromo-4-methoxyphenyl)-7-(cyclopentylamino)pyrazolo[1,5-a]pyridin-3-yl]-3-(dimethylamino)prop-2-en-1-one Chemical compound C1=C(Br)C(OC)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C(=O)\C=C\N(C)C UQCOEWMOQOBMLV-BUHFOSPRSA-N 0.000 description 3
- IJCRZHIMFOCSCA-YIXHJXPBSA-N (e)-1-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methylbut-2-en-1-ol Chemical compound N=1N2C(Cl)=CC=CC2=C(C(O)C(/C)=C/C)C=1C1=CC=CC(C)=C1 IJCRZHIMFOCSCA-YIXHJXPBSA-N 0.000 description 3
- IETNHSPOLWOZRK-YIXHJXPBSA-N (e)-1-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methylbut-2-en-1-one Chemical compound N=1N2C(Cl)=CC=CC2=C(C(=O)C(/C)=C/C)C=1C1=CC=CC(C)=C1 IETNHSPOLWOZRK-YIXHJXPBSA-N 0.000 description 3
- IJCRZHIMFOCSCA-PQMHYQBVSA-N (z)-1-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methylbut-2-en-1-ol Chemical compound N=1N2C(Cl)=CC=CC2=C(C(O)C(\C)=C/C)C=1C1=CC=CC(C)=C1 IJCRZHIMFOCSCA-PQMHYQBVSA-N 0.000 description 3
- PBKONEOXTCPAFI-UHFFFAOYSA-N 1,2,4-trichlorobenzene Chemical compound ClC1=CC=C(Cl)C(Cl)=C1 PBKONEOXTCPAFI-UHFFFAOYSA-N 0.000 description 3
- JNLDACWSVVKSDW-UHFFFAOYSA-N 1-(3-bromo-4-chlorophenyl)-2-(6-chloropyridin-2-yl)ethanone Chemical compound ClC1=CC=CC(CC(=O)C=2C=C(Br)C(Cl)=CC=2)=N1 JNLDACWSVVKSDW-UHFFFAOYSA-N 0.000 description 3
- PTBJOOYLMMCLFQ-UHFFFAOYSA-N 1-(3-bromo-4-methoxyphenyl)-2-(6-chloropyridin-2-yl)ethanone Chemical compound C1=C(Br)C(OC)=CC=C1C(=O)CC1=CC=CC(Cl)=N1 PTBJOOYLMMCLFQ-UHFFFAOYSA-N 0.000 description 3
- JTNKPESREHKERS-UHFFFAOYSA-N 1-(4-bromophenyl)-2-(6-chloropyridin-2-yl)ethanone Chemical compound ClC1=CC=CC(CC(=O)C=2C=CC(Br)=CC=2)=N1 JTNKPESREHKERS-UHFFFAOYSA-N 0.000 description 3
- QNTVSAOTWQXGLY-UHFFFAOYSA-N 1-[2-(2-bromophenyl)-7-(cyclopentylamino)pyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound C=1C=CC2=C(C(=O)C)C(C=3C(=CC=CC=3)Br)=NN2C=1NC1CCCC1 QNTVSAOTWQXGLY-UHFFFAOYSA-N 0.000 description 3
- YJRSOZYVPRXLFF-UHFFFAOYSA-N 1-[2-(2-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound N=1N2C(Cl)=CC=CC2=C(C(=O)C)C=1C1=CC=CC=C1Br YJRSOZYVPRXLFF-UHFFFAOYSA-N 0.000 description 3
- LXTQLOCPYFAHLT-UHFFFAOYSA-N 1-[2-(3-bromo-4-chlorophenyl)-7-(cyclopentylamino)pyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound C=1C=CC2=C(C(=O)C)C(C=3C=C(Br)C(Cl)=CC=3)=NN2C=1NC1CCCC1 LXTQLOCPYFAHLT-UHFFFAOYSA-N 0.000 description 3
- LWRVHVLQOOWUCC-UHFFFAOYSA-N 1-[2-(3-bromo-4-chlorophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound N=1N2C(Cl)=CC=CC2=C(C(=O)C)C=1C1=CC=C(Cl)C(Br)=C1 LWRVHVLQOOWUCC-UHFFFAOYSA-N 0.000 description 3
- GTHKGMGRSZPEDK-UHFFFAOYSA-N 1-[2-(3-bromo-4-methoxyphenyl)-7-(cyclopentylamino)pyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound C1=C(Br)C(OC)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C(C)=O GTHKGMGRSZPEDK-UHFFFAOYSA-N 0.000 description 3
- FJGFJSISZACVCR-UHFFFAOYSA-N 1-[2-(3-bromo-4-methoxyphenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound C1=C(Br)C(OC)=CC=C1C1=NN(C(Cl)=CC=C2)C2=C1C(C)=O FJGFJSISZACVCR-UHFFFAOYSA-N 0.000 description 3
- BQWGKZWWKJDKEK-UHFFFAOYSA-N 1-[2-(3-bromophenyl)-7-(cyclopentylamino)pyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound C=1C=CC2=C(C(=O)C)C(C=3C=C(Br)C=CC=3)=NN2C=1NC1CCCC1 BQWGKZWWKJDKEK-UHFFFAOYSA-N 0.000 description 3
- JDUVEHKUGJYHKF-UHFFFAOYSA-N 1-[2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]prop-2-yn-1-ol Chemical compound N=1N2C(Cl)=CC=CC2=C(C(C#C)O)C=1C1=CC=CC(Br)=C1 JDUVEHKUGJYHKF-UHFFFAOYSA-N 0.000 description 3
- AWWVPMDMZUQSIH-UHFFFAOYSA-N 1-[2-(3-bromophenyl)-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound C=1C=CC2=C(C(=O)C)C(C=3C=C(Br)C=CC=3)=NN2C=1N1CCCC1 AWWVPMDMZUQSIH-UHFFFAOYSA-N 0.000 description 3
- RUSALXMMPPJKNB-UHFFFAOYSA-N 1-[2-(4-bromophenyl)-7-(butylamino)pyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound N=1N2C(NCCCC)=CC=CC2=C(C(C)=O)C=1C1=CC=C(Br)C=C1 RUSALXMMPPJKNB-UHFFFAOYSA-N 0.000 description 3
- QJFIVRAGJKNLSN-UHFFFAOYSA-N 1-[2-(4-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound N=1N2C(Cl)=CC=CC2=C(C(=O)C)C=1C1=CC=C(Br)C=C1 QJFIVRAGJKNLSN-UHFFFAOYSA-N 0.000 description 3
- FGPUICHAFAPPJV-UHFFFAOYSA-N 1-[7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NC2CCCC2)=CC=C2)C2=C1C(C)=O FGPUICHAFAPPJV-UHFFFAOYSA-N 0.000 description 3
- KPNDYHKFWJKJAH-UHFFFAOYSA-N 1-[7-(cyclopropylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NC2CC2)=CC=C2)C2=C1C(C)=O KPNDYHKFWJKJAH-UHFFFAOYSA-N 0.000 description 3
- GYOFKRWKWXZQJF-UHFFFAOYSA-N 1-[7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]prop-2-yn-1-ol Chemical compound COC1=CC=CC(C=2C(=C3C=CC=C(Cl)N3N=2)C(O)C#C)=C1 GYOFKRWKWXZQJF-UHFFFAOYSA-N 0.000 description 3
- LXNXOVOMRJZKJO-UHFFFAOYSA-N 1-[7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]prop-2-yn-1-one Chemical compound COC1=CC=CC(C=2C(=C3C=CC=C(Cl)N3N=2)C(=O)C#C)=C1 LXNXOVOMRJZKJO-UHFFFAOYSA-N 0.000 description 3
- ZMIVEMFEXHYIPQ-UHFFFAOYSA-N 1-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]prop-2-yn-1-ol Chemical compound CC1=CC=CC(C=2C(=C3C=CC=C(Cl)N3N=2)C(O)C#C)=C1 ZMIVEMFEXHYIPQ-UHFFFAOYSA-N 0.000 description 3
- RUOVOPHOMPFNKA-UHFFFAOYSA-N 1-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]prop-2-yn-1-one Chemical compound CC1=CC=CC(C=2C(=C3C=CC=C(Cl)N3N=2)C(=O)C#C)=C1 RUOVOPHOMPFNKA-UHFFFAOYSA-N 0.000 description 3
- SVWDYFFHCHBXKP-UHFFFAOYSA-N 1-[7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]prop-2-yn-1-ol Chemical compound C1=CC(OC)=CC=C1C1=NN(C(Cl)=CC=C2)C2=C1C(O)C#C SVWDYFFHCHBXKP-UHFFFAOYSA-N 0.000 description 3
- QHLMCRGZKPISBI-UHFFFAOYSA-N 2-(2-bromophenyl)-7-chloropyrazolo[1,5-a]pyridine Chemical compound N=1N2C(Cl)=CC=CC2=CC=1C1=CC=CC=C1Br QHLMCRGZKPISBI-UHFFFAOYSA-N 0.000 description 3
- SYPHWRQINWALNC-UHFFFAOYSA-N 2-(3-bromo-4-chlorophenyl)-7-chloropyrazolo[1,5-a]pyridine Chemical compound C1=C(Br)C(Cl)=CC=C1C1=NN2C(Cl)=CC=CC2=C1 SYPHWRQINWALNC-UHFFFAOYSA-N 0.000 description 3
- SSVBENYJWPQIQY-UHFFFAOYSA-N 2-(3-bromo-4-methoxyphenyl)-7-chloropyrazolo[1,5-a]pyridine Chemical compound C1=C(Br)C(OC)=CC=C1C1=NN2C(Cl)=CC=CC2=C1 SSVBENYJWPQIQY-UHFFFAOYSA-N 0.000 description 3
- YTLJLPALOUPBQZ-UHFFFAOYSA-N 2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridine-3-carbaldehyde Chemical compound N=1N2C(Cl)=CC=CC2=C(C=O)C=1C1=CC=CC(Br)=C1 YTLJLPALOUPBQZ-UHFFFAOYSA-N 0.000 description 3
- GBTOISISHUEIPC-UHFFFAOYSA-N 2-(6-chloropyridin-2-yl)-1-(3-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(C(=O)CC=2N=C(Cl)C=CC=2)=C1 GBTOISISHUEIPC-UHFFFAOYSA-N 0.000 description 3
- MVINIWIJZFEAII-UHFFFAOYSA-N 2-(6-chloropyridin-2-yl)-1-(3-methylphenyl)ethanone Chemical compound CC1=CC=CC(C(=O)CC=2N=C(Cl)C=CC=2)=C1 MVINIWIJZFEAII-UHFFFAOYSA-N 0.000 description 3
- VJNFCNYVSLTMEK-UHFFFAOYSA-N 2-(6-chloropyridin-2-yl)-1-(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1C(=O)CC1=CC=CC(Cl)=N1 VJNFCNYVSLTMEK-UHFFFAOYSA-N 0.000 description 3
- NQPJNTMUPAFNMH-UHFFFAOYSA-N 2-[3-(benzhydrylideneamino)-4-chlorophenyl]-n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound ClC1=CC=C(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)C=C1N=C(C=1C=CC=CC=1)C1=CC=CC=C1 NQPJNTMUPAFNMH-UHFFFAOYSA-N 0.000 description 3
- DLMFRMLYSWAWIQ-UHFFFAOYSA-N 2-[3-(benzhydrylideneamino)phenyl]-n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1CCCC1NC1=NC=CC(C2=C3C=CC=C(NC4CCCC4)N3N=C2C=2C=C(C=CC=2)N=C(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 DLMFRMLYSWAWIQ-UHFFFAOYSA-N 0.000 description 3
- SSHWJSLWQRXJGM-UHFFFAOYSA-N 2-cyclopropylguanidine;sulfuric acid Chemical compound OS(O)(=O)=O.NC(=N)NC1CC1 SSHWJSLWQRXJGM-UHFFFAOYSA-N 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 3
- CHLKODZEUPOEFV-UHFFFAOYSA-N 4-[2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]-n-cyclopentylpyrimidin-2-amine Chemical compound N=1N2C(Cl)=CC=CC2=C(C=2N=C(NC3CCCC3)N=CC=2)C=1C1=CC=CC(Br)=C1 CHLKODZEUPOEFV-UHFFFAOYSA-N 0.000 description 3
- VQPKUEUHAHYXFR-UHFFFAOYSA-N 4-[2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]-n-cyclopropylpyrimidin-2-amine Chemical compound N=1N2C(Cl)=CC=CC2=C(C=2N=C(NC3CC3)N=CC=2)C=1C1=CC=CC(Br)=C1 VQPKUEUHAHYXFR-UHFFFAOYSA-N 0.000 description 3
- VASZEEZZHKXMSV-UHFFFAOYSA-N 4-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-n-cyclopentylpyrimidin-2-amine Chemical compound CC1=CC=CC(C=2C(=C3C=CC=C(Cl)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 VASZEEZZHKXMSV-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- CTPVGJWGZXELNZ-UHFFFAOYSA-N 4-[[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butan-1-ol Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCCCO)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 CTPVGJWGZXELNZ-UHFFFAOYSA-N 0.000 description 3
- LPGOIVZOZZKUNR-ADXNAEDLSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[4-[[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]pentanamide Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCCCNC(=O)CCCC[C@H]2[C@H]3NC(=O)N[C@H]3CS2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 LPGOIVZOZZKUNR-ADXNAEDLSA-N 0.000 description 3
- QJJOAIDCNXLVSP-UHFFFAOYSA-N 7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridine Chemical compound COC1=CC=CC(C2=NN3C(Cl)=CC=CC3=C2)=C1 QJJOAIDCNXLVSP-UHFFFAOYSA-N 0.000 description 3
- MAAGVKIGOMECOO-UHFFFAOYSA-N 7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridine-3-carbaldehyde Chemical compound COC1=CC=CC(C=2C(=C3C=CC=C(Cl)N3N=2)C=O)=C1 MAAGVKIGOMECOO-UHFFFAOYSA-N 0.000 description 3
- AOZZHHJQKIZBDT-UHFFFAOYSA-N 7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridine Chemical compound CC1=CC=CC(C2=NN3C(Cl)=CC=CC3=C2)=C1 AOZZHHJQKIZBDT-UHFFFAOYSA-N 0.000 description 3
- HVGNZPOZOATEOD-UHFFFAOYSA-N 7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine-3-carbaldehyde Chemical compound C1=CC(OC)=CC=C1C1=NN(C(Cl)=CC=C2)C2=C1C=O HVGNZPOZOATEOD-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000711557 Hepacivirus Species 0.000 description 3
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 150000003973 alkyl amines Chemical group 0.000 description 3
- 125000005189 alkyl hydroxy group Chemical group 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- CNRRUIFDIALPBB-UHFFFAOYSA-N dibenzyl 4-[[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl phosphate Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCCCOP(=O)(OCC=2C=CC=CC=2)OCC=2C=CC=CC=2)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 CNRRUIFDIALPBB-UHFFFAOYSA-N 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002140 halogenating effect Effects 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 3
- 239000011968 lewis acid catalyst Substances 0.000 description 3
- LROBJRRFCPYLIT-UHFFFAOYSA-M magnesium;ethyne;bromide Chemical compound [Mg+2].[Br-].[C-]#C LROBJRRFCPYLIT-UHFFFAOYSA-M 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- BVECEOUNWXHECP-UHFFFAOYSA-N n-[1-(2-bromophenyl)-2-(6-chloropyridin-2-yl)ethylidene]hydroxylamine Chemical compound C=1C=CC=C(Br)C=1C(=NO)CC1=CC=CC(Cl)=N1 BVECEOUNWXHECP-UHFFFAOYSA-N 0.000 description 3
- HOACKJDYHSOYCC-UHFFFAOYSA-N n-[1-(3-bromo-4-chlorophenyl)-2-(6-chloropyridin-2-yl)ethylidene]hydroxylamine Chemical compound C=1C=C(Cl)C(Br)=CC=1C(=NO)CC1=CC=CC(Cl)=N1 HOACKJDYHSOYCC-UHFFFAOYSA-N 0.000 description 3
- FRAKCFOUSDWIGG-UHFFFAOYSA-N n-[1-(3-bromo-4-methoxyphenyl)-2-(6-chloropyridin-2-yl)ethylidene]hydroxylamine Chemical compound C1=C(Br)C(OC)=CC=C1C(=NO)CC1=CC=CC(Cl)=N1 FRAKCFOUSDWIGG-UHFFFAOYSA-N 0.000 description 3
- JUPZDNHBBCUQGU-UHFFFAOYSA-N n-[1-(4-bromophenyl)-2-(6-chloropyridin-2-yl)ethylidene]hydroxylamine Chemical compound C=1C=C(Br)C=CC=1C(=NO)CC1=CC=CC(Cl)=N1 JUPZDNHBBCUQGU-UHFFFAOYSA-N 0.000 description 3
- KQWDLAJZQVMRDP-UHFFFAOYSA-N n-[2-(6-chloropyridin-2-yl)-1-(3-methoxyphenyl)ethylidene]hydroxylamine Chemical compound COC1=CC=CC(C(CC=2N=C(Cl)C=CC=2)=NO)=C1 KQWDLAJZQVMRDP-UHFFFAOYSA-N 0.000 description 3
- RIFMYZUPINHFBR-UHFFFAOYSA-N n-[2-(6-chloropyridin-2-yl)-1-(3-methylphenyl)ethylidene]hydroxylamine Chemical compound CC1=CC=CC(C(CC=2N=C(Cl)C=CC=2)=NO)=C1 RIFMYZUPINHFBR-UHFFFAOYSA-N 0.000 description 3
- FHGQNCCDHOCKSP-UHFFFAOYSA-N n-[2-(6-chloropyridin-2-yl)-1-(4-methoxyphenyl)ethylidene]hydroxylamine Chemical compound C1=CC(OC)=CC=C1C(=NO)CC1=CC=CC(Cl)=N1 FHGQNCCDHOCKSP-UHFFFAOYSA-N 0.000 description 3
- GGPCJUKYKAVAEX-UHFFFAOYSA-N n-[2-[[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]ethyl]methanesulfonamide Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCNS(C)(=O)=O)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 GGPCJUKYKAVAEX-UHFFFAOYSA-N 0.000 description 3
- LCPCVBSYINGKBU-UHFFFAOYSA-N n-butyl-3-[2-(butylamino)pyrimidin-4-yl]-2-[4-[(4-methoxyphenyl)methylamino]phenyl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(NCC=3C=CC(OC)=CC=3)=CC=2)=N1 LCPCVBSYINGKBU-UHFFFAOYSA-N 0.000 description 3
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 2
- JVBIZHWSPXENIM-CCEZHUSRSA-N (e)-1-[2-(2-bromophenyl)-7-(cyclopentylamino)pyrazolo[1,5-a]pyridin-3-yl]-3-(dimethylamino)prop-2-en-1-one Chemical compound C=1C=CC2=C(C(=O)/C=C/N(C)C)C(C=3C(=CC=CC=3)Br)=NN2C=1NC1CCCC1 JVBIZHWSPXENIM-CCEZHUSRSA-N 0.000 description 2
- TVCYMPSMNBWCSN-FYWRMAATSA-N (e)-1-[2-(4-bromophenyl)-7-(butylamino)pyrazolo[1,5-a]pyridin-3-yl]-3-(dimethylamino)prop-2-en-1-one Chemical compound N=1N2C(NCCCC)=CC=CC2=C(C(=O)\C=C\N(C)C)C=1C1=CC=C(Br)C=C1 TVCYMPSMNBWCSN-FYWRMAATSA-N 0.000 description 2
- DPXTWULZOOIVQO-BUHFOSPRSA-N (e)-1-[7-(cyclopropylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-3-(dimethylamino)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NC2CC2)=CC=C2)C2=C1C(=O)\C=C\N(C)C DPXTWULZOOIVQO-BUHFOSPRSA-N 0.000 description 2
- IETNHSPOLWOZRK-PQMHYQBVSA-N (z)-1-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methylbut-2-en-1-one Chemical compound N=1N2C(Cl)=CC=CC2=C(C(=O)C(\C)=C/C)C=1C1=CC=CC(C)=C1 IETNHSPOLWOZRK-PQMHYQBVSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 2
- PTRBBJDYNGRUAB-UHFFFAOYSA-N 1-(2-bromophenyl)-2-(6-chloropyridin-2-yl)ethanone Chemical compound ClC1=CC=CC(CC(=O)C=2C(=CC=CC=2)Br)=N1 PTRBBJDYNGRUAB-UHFFFAOYSA-N 0.000 description 2
- XYGNZZKFLHOITL-UHFFFAOYSA-N 1-[2-(4-methoxyphenyl)-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-3-yl]ethanone Chemical compound C1=CC(OC)=CC=C1C1=NN(C(=CC=C2)N3CCCC3)C2=C1C(C)=O XYGNZZKFLHOITL-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- ZHKJHQBOAJQXQR-UHFFFAOYSA-N 1H-azirine Chemical compound N1C=C1 ZHKJHQBOAJQXQR-UHFFFAOYSA-N 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- HTAHLXOEHLWANV-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-cyclopentyl-3-[2-(cyclopropylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound ClC1=CC=CC(C=2C(=C3C=CC=C(NC4CCCC4)N3N=2)C=2N=C(NC3CC3)N=CC=2)=C1 HTAHLXOEHLWANV-UHFFFAOYSA-N 0.000 description 2
- FPCJNWCMEYGIPD-UHFFFAOYSA-N 2-(4-bromophenyl)-7-chloropyrazolo[1,5-a]pyridine Chemical compound N=1N2C(Cl)=CC=CC2=CC=1C1=CC=C(Br)C=C1 FPCJNWCMEYGIPD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GPKMSKCINGWCCC-UHFFFAOYSA-N 2-[4-(benzhydrylideneamino)phenyl]-n-butyl-3-[2-(butylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(=CC=2)N=C(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 GPKMSKCINGWCCC-UHFFFAOYSA-N 0.000 description 2
- VQMBTDRVJJEGMV-UHFFFAOYSA-N 2-[4-[bis(cyclopropylmethyl)amino]phenyl]-n-butyl-3-[2-(butylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-7-amine Chemical compound CCCCNC1=NC=CC(C2=C3C=CC=C(NCCCC)N3N=C2C=2C=CC(=CC=2)N(CC2CC2)CC2CC2)=N1 VQMBTDRVJJEGMV-UHFFFAOYSA-N 0.000 description 2
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 2
- QMVMSRWJIQROTI-UHFFFAOYSA-N 3-[2-(cyclopentylamino)pyrimidin-4-yl]-n-cyclopropyl-2-(3-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound FC1=CC=CC(C=2C(=C3C=CC=C(NC4CC4)N3N=2)C=2N=C(NC3CCCC3)N=CC=2)=C1 QMVMSRWJIQROTI-UHFFFAOYSA-N 0.000 description 2
- OSYQSHRKBJLVHE-UHFFFAOYSA-N 4-[2-[3-(benzhydrylideneamino)phenyl]-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-3-yl]-n-cyclopentylpyrimidin-2-amine Chemical compound C1CCCC1NC1=NC=CC(C2=C3C=CC=C(N3N=C2C=2C=C(C=CC=2)N=C(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCCC2)=N1 OSYQSHRKBJLVHE-UHFFFAOYSA-N 0.000 description 2
- LWZUYXVMXCJBQD-UHFFFAOYSA-N 4-[4-[[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butylamino]-4-oxobutanoic acid Chemical compound C1=CC(OC)=CC=C1C1=NN(C(NCCCCNC(=O)CCC(O)=O)=CC=C2)C2=C1C1=CC=NC(NC2CCCC2)=N1 LWZUYXVMXCJBQD-UHFFFAOYSA-N 0.000 description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 229910052684 Cerium Inorganic materials 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- FHUODBDRWMIBQP-UHFFFAOYSA-N Ethyl p-anisate Chemical compound CCOC(=O)C1=CC=C(OC)C=C1 FHUODBDRWMIBQP-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 208000001860 Eye Infections Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000001688 Herpes Genitalis Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010037898 Rash vesicular Diseases 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000005899 aromatization reaction Methods 0.000 description 2
- 150000001543 aryl boronic acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000001542 azirines Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- ZZTURJAZCMUWEP-UHFFFAOYSA-N diaminomethylideneazanium;hydrogen sulfate Chemical compound NC(N)=N.OS(O)(=O)=O ZZTURJAZCMUWEP-UHFFFAOYSA-N 0.000 description 2
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical group C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 208000011323 eye infectious disease Diseases 0.000 description 2
- 229960002089 ferrous chloride Drugs 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000022244 formylation Effects 0.000 description 2
- 238000006170 formylation reaction Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 201000004946 genital herpes Diseases 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 235000015220 hamburgers Nutrition 0.000 description 2
- 229940094991 herring sperm dna Drugs 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical group [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- DBNQIOANXZVWIP-UHFFFAOYSA-N n,n-dimethyl-1,1-bis[(2-methylpropan-2-yl)oxy]methanamine Chemical compound CC(C)(C)OC(N(C)C)OC(C)(C)C DBNQIOANXZVWIP-UHFFFAOYSA-N 0.000 description 2
- GBJWHPAZVVLUIK-UHFFFAOYSA-N n-[1-(3-bromophenyl)-2-(6-chloropyridin-2-yl)ethylidene]hydroxylamine Chemical compound C=1C=CC(Br)=CC=1C(=NO)CC1=CC=CC(Cl)=N1 GBJWHPAZVVLUIK-UHFFFAOYSA-N 0.000 description 2
- SGECHWQKWQJBAO-UHFFFAOYSA-N n-bis(phenylmethoxy)phosphoryl-n-propan-2-ylpropan-2-amine Chemical compound C=1C=CC=CC=1COP(=O)(N(C(C)C)C(C)C)OCC1=CC=CC=C1 SGECHWQKWQJBAO-UHFFFAOYSA-N 0.000 description 2
- UMHKXOZBLQTJHM-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(3-pyridin-4-ylphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1CCCC1NC1=NC=CC(C2=C3C=CC=C(NC4CCCC4)N3N=C2C=2C=C(C=CC=2)C=2C=CN=CC=2)=N1 UMHKXOZBLQTJHM-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- ZAEXDOPLWDCPND-UHFFFAOYSA-N 2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound COC1=CC=C(C=C1)C1=NN2C(C=CC=C2N)=C1 ZAEXDOPLWDCPND-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- QHYGFUYNHIWHLC-UHFFFAOYSA-N 2-butylguanidine;sulfuric acid Chemical compound OS(O)(=O)=O.CCCCN=C(N)N QHYGFUYNHIWHLC-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- AFYKGCFGZVJIQB-UHFFFAOYSA-N 4-cyclopentylpyrimidin-2-amine Chemical compound NC1=NC=CC(C2CCCC2)=N1 AFYKGCFGZVJIQB-UHFFFAOYSA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- VLJQDHDVZJXNQL-UHFFFAOYSA-N 4-methyl-n-(oxomethylidene)benzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N=C=O)C=C1 VLJQDHDVZJXNQL-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- AOIKOZBHESEFEZ-UHFFFAOYSA-N CCCCNc([n]1nc2-c3ccc(C(C)C)cc3)cccc1c2-c1ccnc(NCCCC)n1 Chemical compound CCCCNc([n]1nc2-c3ccc(C(C)C)cc3)cccc1c2-c1ccnc(NCCCC)n1 AOIKOZBHESEFEZ-UHFFFAOYSA-N 0.000 description 1
- QPAHIKUQNRRQMP-UHFFFAOYSA-N CCCCNc([n]1nc2-c3ccc(C4(CC4)c4ccccc4)cc3)cccc1c2-c1nc(NCCCC)ncc1 Chemical compound CCCCNc([n]1nc2-c3ccc(C4(CC4)c4ccccc4)cc3)cccc1c2-c1nc(NCCCC)ncc1 QPAHIKUQNRRQMP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010062343 Congenital infection Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 201000000054 Coronary Restenosis Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000005794 Hairy Leukoplakia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- BTNRGLUWZAOHRO-PGMHBOJBSA-N N/C(/NC1CCCC1)=N\C(\c1c(cccc2NC3CCCC3)[n]2nc1-c1cccc(N)c1)=C/F Chemical compound N/C(/NC1CCCC1)=N\C(\c1c(cccc2NC3CCCC3)[n]2nc1-c1cccc(N)c1)=C/F BTNRGLUWZAOHRO-PGMHBOJBSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108700026039 Simplexvirus UL13 Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 101150048584 TRM3 gene Proteins 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000033779 X-linked lymphoproliferative disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- XLQDQRMFMXYSQS-UHFFFAOYSA-N dichloromethane;hydrochloride Chemical compound Cl.ClCCl XLQDQRMFMXYSQS-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- BIHHBTVQFPVSTE-UHFFFAOYSA-N ethyl 2-bromobenzoate Chemical compound CCOC(=O)C1=CC=CC=C1Br BIHHBTVQFPVSTE-UHFFFAOYSA-N 0.000 description 1
- KSEVRYZEZZJQSN-UHFFFAOYSA-N ethyl 3-bromo-4-chlorobenzoate Chemical compound CCOC(=O)C1=CC=C(Cl)C(Br)=C1 KSEVRYZEZZJQSN-UHFFFAOYSA-N 0.000 description 1
- WIKBASVLVJDZNS-UHFFFAOYSA-N ethyl 3-bromo-4-methoxybenzoate Chemical compound CCOC(=O)C1=CC=C(OC)C(Br)=C1 WIKBASVLVJDZNS-UHFFFAOYSA-N 0.000 description 1
- QAUASTLEZAPQTB-UHFFFAOYSA-N ethyl 3-bromobenzoate Chemical compound CCOC(=O)C1=CC=CC(Br)=C1 QAUASTLEZAPQTB-UHFFFAOYSA-N 0.000 description 1
- GSQLMBQLTPEPHD-UHFFFAOYSA-N ethyl 3-methoxybenzoate Chemical compound CCOC(=O)C1=CC=CC(OC)=C1 GSQLMBQLTPEPHD-UHFFFAOYSA-N 0.000 description 1
- WSJNYOVBJSOQST-UHFFFAOYSA-N ethyl 3-methylbenzoate Chemical compound CCOC(=O)C1=CC=CC(C)=C1 WSJNYOVBJSOQST-UHFFFAOYSA-N 0.000 description 1
- XZIAFENWXIQIKR-UHFFFAOYSA-N ethyl 4-bromobenzoate Chemical compound CCOC(=O)C1=CC=C(Br)C=C1 XZIAFENWXIQIKR-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009548 growth disturbance Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FGYXQBPXHQHYNU-UHFFFAOYSA-M magnesium;but-2-ene;bromide Chemical compound [Mg+2].[Br-].CC=[C-]C FGYXQBPXHQHYNU-UHFFFAOYSA-M 0.000 description 1
- UZNGRHDUJIVHQT-UHFFFAOYSA-M magnesium;prop-1-ene;bromide Chemical compound [Mg+2].[Br-].C[C-]=C UZNGRHDUJIVHQT-UHFFFAOYSA-M 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- UVEWQKMPXAHFST-UHFFFAOYSA-N n,1-diphenylmethanimine Chemical compound C=1C=CC=CC=1C=NC1=CC=CC=C1 UVEWQKMPXAHFST-UHFFFAOYSA-N 0.000 description 1
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HWBIMDYVMBXTGW-UHFFFAOYSA-N n-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(3-thiophen-3-ylphenyl)pyrazolo[1,5-a]pyridin-7-amine Chemical compound C1CCCC1NC1=NC=CC(C2=C3C=CC=C(NC4CCCC4)N3N=C2C=2C=C(C=CC=2)C2=CSC=C2)=N1 HWBIMDYVMBXTGW-UHFFFAOYSA-N 0.000 description 1
- OTPXNHRKTKAFCD-UHFFFAOYSA-N n-cyclopentylpyrimidin-2-amine Chemical compound C1CCCC1NC1=NC=CC=N1 OTPXNHRKTKAFCD-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 206010030979 oral hairy leukoplakia Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000004965 peroxy acids Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- XMGMFRIEKMMMSU-UHFFFAOYSA-N phenylmethylbenzene Chemical group C=1C=CC=CC=1[C]C1=CC=CC=C1 XMGMFRIEKMMMSU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 102000012498 secondary active transmembrane transporter activity proteins Human genes 0.000 description 1
- 108040003878 secondary active transmembrane transporter activity proteins Proteins 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- PUMZKOLPJOPGBQ-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonyl]-n-[n'-(trifluoromethylsulfonyl)carbamimidoyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)C(=N)NS(=O)(=O)C(F)(F)F PUMZKOLPJOPGBQ-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229940108442 valtrex Drugs 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27429701P | 2001-03-08 | 2001-03-08 | |
| US274297P | 2001-03-08 | ||
| PCT/US2002/006552 WO2002072581A2 (en) | 2001-03-08 | 2002-03-05 | Pyrazolopyriadine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60201074D1 DE60201074D1 (en) | 2004-09-30 |
| DE60201074T2 true DE60201074T2 (de) | 2005-09-15 |
Family
ID=23047621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60201074T Expired - Fee Related DE60201074T2 (de) | 2001-03-08 | 2002-03-05 | Pyrazolopyridinderivate |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7153855B2 (enExample) |
| EP (1) | EP1366048B1 (enExample) |
| JP (1) | JP2004529119A (enExample) |
| AT (1) | ATE274515T1 (enExample) |
| AU (1) | AU2002248531A1 (enExample) |
| DE (1) | DE60201074T2 (enExample) |
| ES (1) | ES2227451T3 (enExample) |
| WO (1) | WO2002072581A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004525150A (ja) * | 2001-03-30 | 2004-08-19 | スミスクライン ビーチャム コーポレーション | 治療用化合物としてのピラゾロピリジン類の使用 |
| ATE364043T1 (de) * | 2001-09-07 | 2007-06-15 | Smithkline Beecham Corp | Pyrazolo-pyridine für die behandlung von herpes- ansteckungen |
| EP1485385B1 (en) | 2002-03-07 | 2005-08-17 | SmithKline Beecham Corporation | Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them |
| WO2004033454A1 (en) * | 2002-10-03 | 2004-04-22 | Smithkline Beecham Corporation | Therapeutic compounds based on pyrazolopyridine derivatives |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| ES2422263T3 (es) * | 2008-12-19 | 2013-09-10 | Nerviano Medical Sciences Srl | Pirazoles bicíclicos como inhibidores de la proteinquinasa |
| BRPI1011058A2 (pt) * | 2009-05-19 | 2015-08-25 | Dow Agrosciences Llc | Compostos e metodos controlar fungos |
| EP2402336A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
| PL2763993T3 (pl) * | 2011-10-06 | 2017-09-29 | Bayer Intellectual Property Gmbh | Heterocyklilopiry(mi)dynylopirazol |
| MX389591B (es) | 2014-08-29 | 2025-03-20 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA |
| US20220296595A1 (en) | 2019-05-05 | 2022-09-22 | Qilu Regor Therapeutics Inc. | Cdk inhibitors |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0151962A3 (en) | 1984-01-25 | 1985-10-02 | Beecham Group Plc | Pyrazolopyridine derivatives |
| GB8404584D0 (en) | 1984-02-22 | 1984-03-28 | Beecham Group Plc | Compounds |
| GB8404586D0 (en) | 1984-02-22 | 1984-03-28 | Beecham Group Plc | Compounds |
| US5002941A (en) | 1985-12-12 | 1991-03-26 | Smithkline Beecham Corporation | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors |
| US4925849A (en) | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
| US5155114A (en) | 1989-01-23 | 1992-10-13 | Fujisawa Pharmaceutical Company, Ltd. | Method of treatment using pyrazolopyridine compound |
| GB8901423D0 (en) | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
| WO1991000092A1 (en) | 1989-06-13 | 1991-01-10 | Smithkline Beecham Corporation | Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages |
| AU622330B2 (en) | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
| CA2084290A1 (en) | 1990-06-12 | 1991-12-13 | Jerry L. Adams | Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases |
| GB9015764D0 (en) | 1990-07-18 | 1990-09-05 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
| DE4102340A1 (de) * | 1991-01-26 | 1992-07-30 | Bayer Ag | Lichtleitfasern und verfahren zu ihrer herstellung |
| ATE211384T1 (de) | 1991-01-29 | 2002-01-15 | Fujisawa Pharmaceutical Co | Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera |
| GB9107513D0 (en) | 1991-04-10 | 1991-05-29 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
| US5300478A (en) | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| AU694157B2 (en) | 1993-12-29 | 1998-07-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine adenosine antagonists |
| US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
| EA199700209A1 (ru) | 1995-04-04 | 1998-04-30 | Глаксо Груп Лимитед | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА |
| US6342510B1 (en) | 1995-06-12 | 2002-01-29 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist |
| JPH11507670A (ja) | 1995-06-12 | 1999-07-06 | ジー.ディー.サール アンド カンパニー | シクロオキシゲナーゼ−2インヒビターと5−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療 |
| US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| FR2757059B1 (fr) | 1996-12-12 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouvelle application therapeutique des derives du pyrrole |
| FR2757166B1 (fr) | 1996-12-12 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US20020156104A1 (en) | 1997-06-13 | 2002-10-24 | Jerry L. Adams | Novel pyrazole and pyrazoline substituted compounds |
| EP1369421B1 (en) | 1997-09-05 | 2004-11-03 | Glaxo Group Limited | Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives |
| CA2331878A1 (en) | 1998-05-14 | 1999-11-18 | G.D. Searle & Co. | 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors |
| US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
| FR2779724B1 (fr) * | 1998-06-10 | 2001-04-20 | Rhone Poulenc Rorer Sa | Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent |
| WO2000026216A1 (en) | 1998-11-03 | 2000-05-11 | Glaxo Group Limited | Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| AU2661400A (en) | 1999-02-27 | 2000-09-21 | Glaxo Group Limited | Pyrazolopyridines |
| HRP20010934A2 (en) | 1999-06-28 | 2003-06-30 | Janssen Pharmaceutica Nv | Respiratory syncytial virus replication inhibitors |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| AUPQ969800A0 (en) | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| EP1377573B1 (en) | 2000-12-15 | 2005-07-27 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| EP1341788B1 (en) | 2000-12-15 | 2005-08-10 | Glaxo Group Limited | Pyrazolopyridines |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| AU2002305143A1 (en) | 2001-04-27 | 2002-11-11 | Smithkline Beecham Corporation | Pyrazolo'1,5-a!pyridine derivatives |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
-
2002
- 2002-03-05 US US10/468,729 patent/US7153855B2/en not_active Expired - Fee Related
- 2002-03-05 AT AT02717537T patent/ATE274515T1/de not_active IP Right Cessation
- 2002-03-05 WO PCT/US2002/006552 patent/WO2002072581A2/en not_active Ceased
- 2002-03-05 ES ES02717537T patent/ES2227451T3/es not_active Expired - Lifetime
- 2002-03-05 JP JP2002571497A patent/JP2004529119A/ja not_active Ceased
- 2002-03-05 AU AU2002248531A patent/AU2002248531A1/en not_active Abandoned
- 2002-03-05 EP EP02717537A patent/EP1366048B1/en not_active Expired - Lifetime
- 2002-03-05 DE DE60201074T patent/DE60201074T2/de not_active Expired - Fee Related
-
2006
- 2006-08-30 US US11/468,319 patent/US20060293344A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050049260A1 (en) | 2005-03-03 |
| EP1366048B1 (en) | 2004-08-25 |
| AU2002248531A1 (en) | 2002-09-24 |
| WO2002072581A2 (en) | 2002-09-19 |
| JP2004529119A (ja) | 2004-09-24 |
| DE60201074D1 (en) | 2004-09-30 |
| ES2227451T3 (es) | 2005-04-01 |
| ATE274515T1 (de) | 2004-09-15 |
| WO2002072581A3 (en) | 2003-05-01 |
| US7153855B2 (en) | 2006-12-26 |
| EP1366048A2 (en) | 2003-12-03 |
| US20060293344A1 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60204452T2 (de) | Pyrazolo[1,5a]Pyridinderivate | |
| DE60112609T2 (de) | Pyrazolopyridine | |
| DE60214179T2 (de) | Imidazo-1,2-A/Pyriden-Derivate zur Prophylaxe und Behandlung von Herpes-Infektionen | |
| DE60212949T2 (de) | Antivirale pyrazolopyridin verbindungen | |
| DE60220525T2 (de) | Pyrazolo-pyridine für die behandlung von herpes-ansteckungen | |
| DE60112330T2 (de) | Pyrazolopyridinderivate | |
| DE60211539T2 (de) | Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion | |
| DE60301339T2 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
| EP1504004B1 (en) | Substituted pyrazolopyrimidines | |
| US7153863B2 (en) | Therapeutic compounds based on pyrazolopyridline derivatives | |
| EP1372643A1 (en) | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | |
| DE60201074T2 (de) | Pyrazolopyridinderivate | |
| DE60222465T2 (de) | Pyrazolopyridin-derivate als antiherpesmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |